KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) EBT Margin (2016 - 2025)

Historic EBT Margin for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to 13.24%.

  • Boston Scientific's EBT Margin rose 4200.0% to 13.24% in Q4 2025 from the same period last year, while for Dec 2025 it was 16.86%, marking a year-over-year increase of 32300.0%. This contributed to the annual value of 16.86% for FY2025, which is 32400.0% up from last year.
  • Latest data reveals that Boston Scientific reported EBT Margin of 13.24% as of Q4 2025, which was up 4200.0% from 18.54% recorded in Q3 2025.
  • In the past 5 years, Boston Scientific's EBT Margin ranged from a high of 18.59% in Q2 2025 and a low of 3.81% during Q4 2021
  • For the 5-year period, Boston Scientific's EBT Margin averaged around 12.54%, with its median value being 12.96% (2023).
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 250100bps in 2021, then crashed by -87400bps in 2022.
  • Over the past 5 years, Boston Scientific's EBT Margin (Quarter) stood at 3.81% in 2021, then soared by 221bps to 12.21% in 2022, then grew by 11bps to 13.56% in 2023, then fell by -5bps to 12.83% in 2024, then rose by 3bps to 13.24% in 2025.
  • Its EBT Margin was 13.24% in Q4 2025, compared to 18.54% in Q3 2025 and 18.59% in Q2 2025.